Tobias Alpsten, CEO of iPLATO, said: “Continued support from healthcare commissioners across the NHS has been an instrumental in enabling us to reach our first five million patients. However, this is only a step on the way. There are more than 6 billion mobile handsets in the world today, each owned by a person for whom health is important, so there is a lot of room for growth. In addition to our in-house research and development efforts we actively seek partners with specific clinical skills to add to our overall service offering. We owe our healthcare provider partners and patients best-of-breed services. We expect many of these new, exiting, services to be delivered in partnership with universities, hospitals, clinical experts and other innovation companies across the world. We are especially interested in services that support people with long term conditions such as hypertension, diabetes, asthma, depression and coronary heart disease.”

– Ends –

NOTES FOR EDITORS

About iPLATO

iPLATO Healthcare is British innovation company dedicated to mobile health since 2006.

iPLATO’s evidence based mobile health solutions have proven to improve patient access to healthcare, to enable powerful health promotion targeted at people at risk and to support people with long term conditions.

Serving millions of patients and thousands of healthcare professionals every day iPLATO has emerged as the leader in mobile health. Across this network the company is running campaigns to promote smoking cessation, weight loss, childhood immunisation and cancer screening as well as mobile disease management services for people with epilepsy, COPD and HIV.

iPLATO Healthcare’s mission is to, in partnership with healthcare professionals and provider organisations, support patients in achieving longer, healthier lives.

iPLATO Healthcare
1 Lyric Square
London W6 0NB
www.iplato.net
e-mail: info@iplato.net

Pictures available on request